United Therapeutics' COO Reports Sale of Common Stock

Summary

Michael Benkowitz, President and COO of United Therapeutics Corporation, has reported the disposal of common shares of the company. The full filing is available through the provided link. This news was generated by Public Technologies and is for informational purposes only, not to be considered as financial or legal advice. The original content was published by United Therapeutics via EDGAR on September 24, 2025.Reuters

Impact Analysis

So Michael Benkowitz, the President and COO of United Therapeutics, has sold some of his common shares. This is interesting because it comes shortly after analysts raised their target price for the stock from $463 to $500, reflecting a 7.99% increase.AnueSec The timing could suggest a few things: either Benkowitz is capitalizing on the recent price hike, or he might have concerns about the stock’s future performance despite the optimistic analyst outlook. The stock has seen significant volatility recently, with notable gains and losses in the biotech sector.Price Alert+ 2 This disposal might be a personal financial decision, but it could also be a subtle signal about his confidence in the company’s near-term prospects. I’d watch for any further insider sales or changes in analyst ratings as potential indicators of underlying issues or shifts in sentiment. The market might be missing the potential downside risk here, especially if more insiders start selling.